Trading Signals
On What Basis Did Immuron (IMRN) Stock Rise 21% In Extended Session Friday?
In Friday’s after-hours trading, Immuron Limited (NASDAQ: IMRN) shares increased 21.21% to $2.40 as the pharmaceutical company submitted an application for a new medication. Which document has IMRN filed? This month, Immuron (IMRN) said that it has applied for an investigational new drug (IND) designation for Travelan with the US Food and Drug Administration. Immuron will assess the effectiveness of Travelan’s single-dose regimen in a Phase II clinical study utilizing a controlled human infection model (CHIM) and the enterotoxigenic Escherichia coli (ETEC) strain H10407. Up to 60 healthy adult volunteers are expected to participate in the clinical investigation. Each subject
